Affordable Access

Publisher Website

Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas.

Authors
Journal
Filaria Journal
1475-2883
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Volume
2
Identifiers
DOI: 10.1186/1475-2883-2-s1-s1
Keywords
  • Editorial
Disciplines
  • Education

Abstract

1475-2883-2-S1-S1.fm ral ss BioMed CentFilaria Journal Open AcceEditorial Overview: Report of a Scientific Working Group on Serious Adverse Events following Mectizan® treatment of onchocerciasis in Loa loa endemic areas. Brian OL Duke* Address: River Blindness Foundation, 2 Hillside, Lancaster, LA1 1YH, United Kingdom Email: Brian OL Duke* - [email protected] * Corresponding author This report reviews information on Serious Adverse Events (SAE), mainly Loa-encephalopathy, following treatment with ivermectin (Mectizan®, Merck, Sharpe & Dohme) for control of onchocerciasis carried out by the African Pro- gramme for Onchocerciasis Control (APOC), in areas where heavy microfilarial infections with Loa loa are co- endemic with Onchocerca volvulus infections. It also endeavours to define the information and research needed to understand, prevent, and manage cases of Loa- encephalopathy. In coping with the recent appearance of the risk of Loa- encephalopathy, the Mectizan® Expert Committee and its secretariat, the Mectizan® Donation Program (MDP), and the national onchocerciasis control programmes, involv- ing APOC and associated Non-Governmental Develop- ment Organizations (NGDOs), have to assess the benefits of mass treatment in preventing the blindness and unpleasant skin manifestations of onchocerciasis in large numbers of infected persons, against the risk of inciting severe and sometimes fatal reactions of Loa-encephalopa- thy in a small proportion of treated persons living in areas of high Loa co-endemicity. In practical terms, this dilemma raises a number of problems and implies the need for much extra effort and costs in the field prior to, during, and shortly after community distribution of Mec- tizan®. ratio in those communities to be treated by APOC wherein L. loa and O. volvulus are co-endemic, and also more careful control of stocks of Mectizan®. It demands a reinforced health-education campaign in favour of taking Mectizan®. It will mean confining Mectizan® t

There are no comments yet on this publication. Be the first to share your thoughts.